Current Clinical Trials
Without these clinical trials and research, innovative discoveries within the medical field would not make it to the patients that will benefit from them.
Ampio Knee Injection Study
This study is testing the safety and effectiveness of a new investigational treatment for patients with severe knee pain due to osteoarthritis. Study participation is a total of 24 weeks, including 4 visits to the study clinic and 7 phone conversations with study staff. Over the course of the study, you will receive either the active or placebo version of the investigational drug and have doctors monitor your health and progress through study-related tests and assessments. See if you or a loved one qualify today! Call our office at .
Axiomatic Blood Clot Study
The Axiomatic drug trial is an IRB approved phase II, randomized, open label, study drug-dose blind, multicenter study to evaluate the efficacy and safety of JNJ-70033093, an oral factor XIa inhibitor (blood thinner), versus subcutaneous enoxaparin in subjects undergoing elective total knee replacement surgery. JNJ-70033093 is a small-molecule therapeutic agent that binds and inhibits the activated form of human coagulation factor XIa with high affinity and selectivity. It is being developed as an orally administered anticoagulant for the prevention and treatment of thromboembolic events. It is a 6 week participating study consisting of 6 in-office visits
Hipgen Stem Cell Study
The HipGen trial is an IRB approved phase III, multicenter, randomized, double-blind, placebo-controlled study designed to determine the efficacy, safety, and tolerability of intramuscular administration of allogenic PLX-PAD cells following arthroplasty for femoral neck hip fractures. PLX-PAD cells are comprised of ex-vivo explanted placental adherent stromal cells that are derived from human placentae (stem cells). PLX-PAD possesses pro-angiogenic and anti-inflammatory properties, as well as a positive effect on muscle regeneration. It is a two year participation study consisting of eight in-office visits.